top of page
Pharma & Healthcare Investment
Covers pharmaceuticals, biotech, medical devices, diagnostics, healthcare systems, and increasingly AI applied to drug discovery and healthcare. Drug development is long, complex, and science-driven. Understanding the biology, chemistry, and clinical pipeline behind a company tells you more than its balance sheet. This category analyzes pharmaceutical and biotech opportunities through a science-first lens — from molecule to market — so you can read the opportunity before the stock price moves.
U.S.–China Biotech & Life Sciences Sector Analysis
Illumina lost 27% of its China revenue in one quarter after being blacklisted — retaliation for lobbying against its own top competitor, BGI. The company's CEO was the only life sciences executive in Trump's May 2026 Beijing delegation, while Pfizer and Eli Lilly stayed away, already deep in $50 billion of licensing deals that needed no summit at all.
May 21
Investment Scenario Analysis: Eli Lilly (LLY) and Summit Therapeutics (SMMT) Benchmarked Against the S&P 500 Index
SMMT's 5-year bull case reaches 500-1000% — but carries a real scenario of losing nearly everything. LLY, despite an 800% run since 2019, now trades at 38x earnings with a base case barely ahead of the S&P 500. A side-by-side scenario analysis across three completely different risk profiles.
May 7
Tech vs. Pharma: Why Technology Leads S&P 500 Growth — And What It Means for Investors
A tech company's marginal cost of serving one more customer is fractions of a penny. A pharma company's cost scales with every pill manufactured, shipped, and monitored. That single structural difference explains more of the tech-pharma performance gap than any other factor — and it's not the whole story.
May 5
How to Research Pharma Companies Like an Analyst: A Complete Guide to Public Information Sources for Serious Pharmaceutical Investors
Institutional-quality pharma research requires no Bloomberg terminal — it requires knowing that FDA Medical Reviews, R&D Day slide decks, and ClinicalTrials.gov protocols exist, and reading them critically. A complete map of every public source serious pharma investors use, and a step-by-step research workflow you can apply to any company.
May 1
Who Really Decides What Gets Built in Big Pharma? The Decision-Making Architecture Behind Pharmaceutical Platform Strategy
The press release always quotes the CEO — but the AstraZeneca-Daiichi Sankyo ADC deal, arguably pharma's most value-creating business development move of the decade, was found and built by the BD team before Soriot ever saw it. A map of who actually decides what gets built, and why the highest-cost mistakes rarely make headlines.
May 1
The CEOs Behind the Pipelines: Leadership, Background & What Makes a Successful Pharma CEO
Pascal Soriot rejected an 87 billion euro takeover bid in 2014, betting the company's future on a single compound that became Tagrisso. David Ricks calls his leadership approach "bumpers on the bowling alley." Eight pharma CEOs, profiled by leadership archetype — and why matching the right archetype to the right strategic moment matters more than any individual decision.
May 1
Do Mega-Cap Pharma Companies Compete With Each Other?
Lilly and Novo Nordisk fight head-to-head over GLP-1 patients. AbbVie and JNJ never share a patient, yet compete intensely at the payer negotiation table. Two companies can be in the same disease and not compete at all — a five-part framework for understanding what's actually driving pharma competitive dynamics.
May 1
Mega-Cap Pharma Pipeline Differentiation: What Each Company Is Building — And Why It Matters
Lilly's retatruitide hit 29% weight loss in Phase 2 — the highest ever recorded for an obesity drug — while AstraZeneca built the deepest ADC oncology platform through a Daiichi Sankyo partnership. Eight mega-cap pharma pipelines, ranked by which companies are building genuine scientific moats versus catching up from behind.
May 1
Beyond the ETF: Five Niches Where Biotech Beats the S&P 500
Biotech ETFs have underperformed the S&P 500 over both 5- and 10-year periods, with far more volatility — yet the sector still produces 3-20x returns for selective investors. Five distinct return mechanisms explain the paradox, ranked from accessible to non-scientists (M&A basket positioning) to requiring genuine scientific literacy (platform discount investing).
May 1
Biotech ETF Deep Dive: Composition, Returns & Investor Fit
ARKG surged 185% in 2020, then fell 75% peak-to-trough — the most dramatic boom-bust cycle among the four major biotech ETFs. A composition and returns breakdown of XBI, IBB, ARKG, and BBH, mapped to which investor profile each one actually fits.
Apr 29
bottom of page